ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials

References

• De Backer GG. Prevention of cardiovascular disease: much more is needed. Eur J Prev Cardiol. 2018 Jul;25(10):1083–1086. PubMed PMID: 29692207.
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH Jr., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006 Mar 23;354(12):1264–1272. PubMed PMID: 16554528.
   PubMed Web of Science ®Google Scholar
• Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014 Oct;88:3–11. PubMed PMID: 24657242.
   PubMed Web of Science ®Google Scholar
• Pokharel Y, Gosch K, Nambi V, et al. Practice-level variation in statin use among patients with diabetes: insights from the PINNACLE registry. J Am Coll Cardiol. 2016 Sep 20;68(12):1368–1369. PubMed PMID: 27634128; PubMed Central PMCID: PMCPMC5250510.
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol. 2015 Mar–Apr;9(2):129–169. PubMed PMID: 25911072.
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther. 2005 Dec;19(6):403–414. PubMed PMID: 16453090.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Dent-Acosta RE, Rosenson RS, et al. Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial. Clin Cardiol. 2016 Mar;39(3):137–144. PubMed PMID: 26946077.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015 May 1;36(17):1012–1022. PubMed PMID: 25694464; PubMed Central PMCID: PMCPMC4416140.
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel. Arch Med Sci. 2015 Mar 16;11(1):1–23. PubMed PMID: 25861286; PubMed Central PMCID: PMCPMC4379380.
   PubMed Web of Science ®Google Scholar
• Toth PP, Patti AM, Giglio RV, et al. Management of statin intolerance in 2018: still more questions than answers. Am J Cardiovasc Drugs. 2018 Jun;18(3):157–173. PubMed PMID: 29318532; PubMed Central PMCID: PMCPMC5960491.
   PubMed Web of Science ®Google Scholar
• Ito MK, Maki KC, Brinton EA, et al. Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study. J Clin Lipidol. 2014 Jan–Feb;8(1):69–76. . PubMed PMID: 24528687.
   PubMed Web of Science ®Google Scholar
• Mombelli G, Bosisio R, Calabresi L, et al. Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. J Clin Lipidol. 2015 Mar–Apr;9(2):226–233. . PubMed PMID: 25911079.
   PubMed Web of Science ®Google Scholar
• Serban MC, Colantonio LD, Manthripragada AD, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017 Mar 21;69(11):1386–1395. PubMed PMID: 28302290.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015 Jun 18;372(25):2387–2397. PubMed PMID: 26039521.
   PubMed Web of Science ®Google Scholar
• Ference BA, Cannon CP, Landmesser U, et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the cholesterol treatment trialists collaboration. Eur Heart J. 2018 Jul 14;39(27):2540–2545. PubMed PMID: 29020411; PubMed Central PMCID: PMCPMC6047439.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713–1722. PubMed PMID: 28304224.
   PubMed Web of Science ®Google Scholar
• Pocock SJ, Collier TJ. Critical appraisal of the 2018 ACC scientific sessions late-breaking trials from a statistician’s perspective. J Am Coll Cardiol. 2018 Jun 26;71(25):2957–2969. . PubMed PMID: 29753563.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017 Oct 28;390(10106):1962–1971. PubMed PMID: 28859947.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Waters DD. Variations in time to benefit among clinical trials of cholesterol-lowering drugs. J Clin Lipidol. 2018 Jul–Aug;12(4):857–862. . PubMed PMID: 29779997.
   PubMed Web of Science ®Google Scholar
• Bohula EA, Giugliano RP, Leiter LA, et al. Inflammatory and cholesterol risk in the FOURIER trial. Circulation. 2018 Jul 10;138(2):131–140. PubMed PMID: 29530884.
   PubMed Web of Science ®Google Scholar
• Koenig W. Low-grade inflammation modifies cardiovascular risk even at very low LDL-C levels: are we aiming for a dual target concept? Circulation. 2018 Jul 10;138(2):150–153. PubMed PMID: 29986958.
   PubMed Web of Science ®Google Scholar
• Esperion announces agreement with Daiichi Sankyo Europe (DSE) to commercialize bempedoic acid in Europe [Internet]. 2019. [cited 2019 Feb 22]. Available from: https://investor.esperion.com/news-releases/news-release-details/esperion-announces-agreement-daiichi-sankyo-europe-dse
   Google Scholar
• Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016 Nov 28; 7:13457. PubMed PMID: 27892461; PubMed Central PMCID: PMCPMC5133702 from Esperion Therapeutics, Inc. The remaining authors declare no competing financial interests.
   PubMed Web of Science ®Google Scholar
• Paton D. Bempedoic Acid: ATP-citrate lyase inhibitor. Drugs Future. 2017;42(4):8.
   Web of Science ®Google Scholar
• Bilen O, Ballantyne CM. Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase. Curr Atheroscler Rep. 2016 Oct;18(10):61. . PubMed PMID: 27663902; PubMed Central PMCID: PMCPMC5035316.
   PubMed Web of Science ®Google Scholar
• Watson JA, Fang M, Lowenstein JM. Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase. Arch Biochem Biophys. 1969 Dec;135(1):209–217. PubMed PMID: 5362924.
   PubMed Web of Science ®Google Scholar
• Linn TC, Srere PA. Binding of ATP citrate lyase to the microsomal fraction of rat liver. J Biol Chem. 1984 Nov 10;259(21):13379–13384. PubMed PMID: 6490657.
   PubMed Web of Science ®Google Scholar
• Linn TC, Srere PA. Identification of ATP citrate lyase as a phosphoprotein. J Biol Chem. 1979 Mar 10;254(5):1691–1698. PubMed PMID: 762167.
   PubMed Web of Science ®Google Scholar
• Burke AC, Huff MW. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia. Curr Opin Lipidol. 2017 Apr;28(2):193–200. . PubMed PMID: 28059952.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Groot PHE, Lalwani ND, et al. Targeting ATP-citrate lyase in hyperlipidemia and metabolic disorders. Trends Mol Med. 2017 Nov;23(11):1047–1063. PubMed PMID: 28993031.
   PubMed Web of Science ®Google Scholar
• Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 2019 Feb;30(1):1–9. PubMed PMID: 30586346.
   PubMed Web of Science ®Google Scholar
• Sato R, Okamoto A, Inoue J, et al. Transcriptional regulation of the ATP citrate-lyase gene by sterol regulatory element-binding proteins. J Biol Chem. 2000 Apr 28;275(17):12497–12502. PubMed PMID: 10777536.
   PubMed Web of Science ®Google Scholar
• Covarrubias AJ, Aksoylar HI, Yu J, et al. Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. Elife. 2016 Feb 19;5. PubMed PMID: 26894960; PubMed Central PMCID: PMCPMC4769166. DOI:10.7554/eLife.11612
   PubMed Web of Science ®Google Scholar
• Beigneux AP, Kosinski C, Gavino B, et al. ATP-citrate lyase deficiency in the mouse. J Biol Chem. 2004 Mar 5;279(10):9557–9564. PubMed PMID: 14662765; PubMed Central PMCID: PMCPMC2888281.
   PubMed Web of Science ®Google Scholar
• Cramer CT, Goetz B, Hopson KL, et al. Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome. J Lipid Res. 2004 Jul;45(7):1289–1301. PubMed PMID: 15102884.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013 Jan;54(1):134–151. PubMed PMID: 23118444; PubMed Central PMCID: PMCPMC3520520.
   PubMed Web of Science ®Google Scholar
• Gutierrez MJ, Rosenberg NL, Macdougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):676–683. PubMed PMID: 24385236.
   PubMed Web of Science ®Google Scholar
• Filippov S, Pinkosky SL, Lister RJ, et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J Lipid Res. 2013 Aug;54(8):2095–2108. PubMed PMID: 23709692; PubMed Central PMCID: PMCPMC3708360.
   PubMed Web of Science ®Google Scholar
• Jeong HW, Hsu KC, Lee JW, et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E955–E964. PubMed PMID: 19208854.
   PubMed Web of Science ®Google Scholar
• Samsoondar JP, Burke AC, Sutherland BG, et al. Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in Ldlr(-/-) mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid. Arterioscler Thromb Vasc Biol. 2017 Apr;37(4):647–656. PubMed PMID: 28153881.
   PubMed Web of Science ®Google Scholar
• Burke AC, Telford DE, Sutherland BG, et al. Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (LDLR(±) and LDLR(-/-)) Yucatan miniature pigs. Arterioscler Thromb Vasc Biol. 2018 May;38(5):1178–1190. PubMed PMID: 29449335.
   PubMed Web of Science ®Google Scholar
• Penson P, McGowan M, Banach M. Evaluating bempedoic acid for the treatment of hyperlipidaemia. Expert Opin Investig Drugs. 2017 Feb;26(2):251–259. . PubMed PMID: 28064554.
   PubMed Web of Science ®Google Scholar
• MacDougall D, Vanderlugt J, Rosenberg N, et al. ETC-1002, a modulator of adenosine monophosphate-activated protein kinase and adenosine triphosphate-citrate lyase, was safe and reduced low-density lipoprotein-cholesterol in healthy volunteers. J Am Coll Cardiol. 2013;61(10Supplement). DOI:10.1016/S0735-1097(13)61463-1
   Google Scholar
• Nikolic D, Mikhailidis DP, Davidson MH, et al. ETC-1002: a future option for lipid disorders? Atherosclerosis. 2014 Dec;237(2):705–710. PubMed PMID: 25463109.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24;62(13):1154–1162. PubMed PMID: 23770179.
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Sirtori CR, et al. Present therapeutic role of cholesteryl ester transfer protein inhibitors. Pharmacol Res. 2018 Feb;128:29–41. PubMed PMID: 29287689.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Rubino J, Janik MJ, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015 May–Jun;9(3):295–304. PubMed PMID: 26073387.
   PubMed Web of Science ®Google Scholar
• Newton RS, Thompson PD, Macdougall DE, et al. ETC-1002 lowers LDL-cholesterol and is well tolerated in hypercholesterolemic patients with statin intolerance. J Clin Lipidol. 2014;8(3):1.
   PubMedGoogle Scholar
• Thompson PD, MacDougall DE, Newton RS, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016 May–Jun;10(3):556–567. PubMed PMID: 27206943.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, McKenney JM, MacDougall DE, et al. Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy. Am J Cardiol. 2016 Jun 15;117(12):1928–1933. PubMed PMID: 27138185.
   PubMed Web of Science ®Google Scholar
• Saeed A, Ballantyne CM. Bempedoic acid (ETC-1002): a current review. Cardiol Clin. 2018 May;36(2):257–264. PubMed PMID: 29609755.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018 Oct;277:195–203. PubMed PMID: 29910030.
   PubMed Web of Science ®Google Scholar
• Zagelbaum NK, Yandrapalli S, Nabors C, et al. Bempedoic acid (ETC-1002): ATP citrate lyase inhibitor: review of a first in class medication with potential benefit in statin-refractory cases. Cardiol Rev. 2018 Jun 22. PubMed PMID: 29939848. DOI:10.1097/CRD.0000000000000218
   Web of Science ®Google Scholar
• Esperion. Esperion announces positive top-line results from final pivotal phase 3 study of bempedoic acid. 2018 [cited 2018 Oct 31]. Available from: http://investor.esperion.com/news-releases/news-release-details/esperion-announces-positive-top-line-results-final-pivotal-phase
   Google Scholar
• NCT02988115. Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) in patients with hyperlipidemia and statin intolerant (CLEAR serenity). [cited 2019 Feb 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT02988115
   Google Scholar
• Laufs U, Banach M, Mancini J, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. 2018. Available from: http://abstractsonline.com/pp8/#!/4682/presentation/59949
   Google Scholar
• Macchi C, Banach M, Corsini A, et al. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents. Eur J Prev Cardiol. 2019 Feb 18:2047487319831500. doi: 10.1177/2047487319831500.
   Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267–1278. PubMed PMID: 16214597.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Ray KK, Grobbee DE. Will genetic studies deliver the next generation of cardioprotective therapies? Eur J Prev Cardiol. 2017 Mar;24(5):489–491. PubMed PMID: 28121171.
   PubMed Web of Science ®Google Scholar
• Ference BA. How to use Mendelian randomization to anticipate the results of randomized trials. Eur Heart J. 2018 Feb 1;39(5):360–362. . PubMed PMID: 29020392.
   PubMed Web of Science ®Google Scholar
• Ference BA, Neff D, Cabot M, et al. Genetic target validation for ATP-citrate lyase inhibition. J Am Coll Cardiol. 2017 Mar 19;69(11).
   Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017 Aug 21;38(32):2459–2472. PubMed PMID: 28444290; PubMed Central PMCID: PMCPMC5837225.
   PubMed Web of Science ®Google Scholar
• Danchin N, Almahmeed W, Al-Rasadi K, et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: the International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol. 2018 Jul;25(10):1087–1094. PubMed PMID: 29771156; PubMed Central PMCID: PMCPMC6039862.
   PubMed Web of Science ®Google Scholar
• Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995 May;15(5):551–561. PubMed PMID: 7749869; PubMed Central PMCID: PMCPMC2924812.
   PubMed Web of Science ®Google Scholar
• Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016 Sep 27;316(12):1289–1297. PubMed PMID: 27673306.
   PubMed Web of Science ®Google Scholar
• Ference BA, Graham I, Tokgozoglu L, et al. Impact of lipids on cardiovascular health: JACC health promotion series. J Am Coll Cardiol. 2018 Sep 4;72(10):1141–1156. PubMed PMID: 30165986.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists C, Fulcher J, O’Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015 Apr 11;385(9976):1397–1405. PubMed PMID: 25579834.
   PubMed Web of Science ®Google Scholar
• Berkhout TA, Havekes LM, Pearce NJ, et al. The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2. Biochem J. 1990 Nov 15;272(1):181–186. PubMed PMID: 2176080; PubMed Central PMCID: PMCPMC1149674.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Macchi C, Pavanello C, et al. Appropriateness of statin prescription in the elderly. Eur J Intern Med. 2018 Apr;50:33–40. PubMed PMID: 29310996.
   PubMed Web of Science ®Google Scholar
• Magni P, Macchi C, Morlotti B, et al. Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Eur J Intern Med. 2015 Mar;26(2):82–88. PubMed PMID: 25640999.
   PubMed Web of Science ®Google Scholar
• Bellosta S, Ferri N, Bernini F, et al. Non-lipid-related effects of statins. Ann Med. 2000 Apr;32(3):164–176. PubMed PMID: 10821323.
   PubMed Web of Science ®Google Scholar
• Wang M, Casey PJ. Protein prenylation: unique fats make their mark on biology. Nat Rev Mol Cell Biol. 2016 Feb;17(2):110–122. PubMed PMID: 26790532.
   PubMed Web of Science ®Google Scholar
• Corsini A, Pazzucconi F, Pfister P, et al. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet. 1996 Dec 7;348(9041):1584. PubMed PMID: 8950895.
   PubMed Web of Science ®Google Scholar
• Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis. 1993 Jun;101(1):117–125. PubMed PMID: 8216498.
   PubMed Web of Science ®Google Scholar
• Elam MB, Majumdar G, Mozhui K, et al. Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. PLoS One. 2017;12(8):e0181308. PubMed PMID: 28771594; PubMed Central PMCID: PMCPMC5542661.
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2017 Oct 3;70(14):1785–1822. PubMed PMID: 28886926.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Baker S, Banach M, et al. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol. 2017 Sep 5;70(10):1290–1301. PubMed PMID: 28859793.
   PubMed Web of Science ®Google Scholar
• Authors/Task, Force M, Piepoli MF, Hoes AW, et al. European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016 Jul;23(11):NP1–NP96. PubMed PMID: 27353126.
   PubMed Web of Science ®Google Scholar
• Drexel H. Cost-effectiveness with PCSK9 inhibitors: a matter of costs. Eur Heart J Cardiovasc Pharmacother. 2018 Jan 1;4(1):23–24. . PubMed PMID: 29315397.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Ferri N, Corsini A, et al. PCSK9 antagonists and inflammation. Atherosclerosis. 2018 Jan;268:235–236. PubMed PMID: 29102656.
   PubMed Web of Science ®Google Scholar
• Ruscica M, Ferri N, Macchi C, et al. Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes? Ann Med. 2018 Oct 15:1–24. PubMed PMID: 29976096. DOI:10.1080/07853890.2018.1498118
   PubMed Web of Science ®Google Scholar
• Penson PE, Long DL, Howard G, et al. Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the reasons for geographical and racial differences in stroke (REGARDS) study. Eur Heart J. 2018 Oct 21;39(40):3641–3653. PubMed PMID: 30165636; PubMed Central PMCID: PMCPMC6195947.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017 Sep 21;377(12):1119–1131. PubMed PMID: 28845751.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Pradhan A, et al. Low-Dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2018 Nov 10. PubMed PMID: 30415610.. DOI:10.1056/NEJMoa1809798
   Web of Science ®Google Scholar
• Navarese EP, Andreotti F, Raggi P, et al. Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. Eur Heart J Cardiovasc Pharmacother. 2018 Sep 21. PubMed PMID: 30247574. DOI:10.1093/ehjcvp/pvy038
   PubMed Web of Science ®Google Scholar